Jennifer Laporta, MD
Family Medicine · Tinton Falls, NJNPI 1538587563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations.
Across 254 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$945
- AbbVie$667
- AstraZeneca$412
- GSK$354
- Exact Sciences$252
- Lilly USA, LLC$221
- plus $1K from 19 others
Across 1 payment — averaging $250.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$251
What the payments were for
- Food & beverage$4,038100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 61 | $945 |
| AbbVie(2 entities) | 45 | $667 |
| AstraZeneca | 25 | $412 |
| GSK | 23 | $354 |
| Exact Sciences | 9 | $252 |
| Lilly USA, LLC | 15 | $221 |
| Phathom Pharmaceuticals, Inc. | 15 | $211 |
| Pfizer | 12 | $204 |
| Amgen | 11 | $171 |
| Bayer | 6 | $109 |
| Boehringer Ingelheim | 5 | $80 |
| Daiichi Sankyo Inc. | 5 | $71 |
| Merck | 4 | $57 |
| Genentech USA, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 3 | $39 |
| Dynavax Technologies Corporation | 3 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Abbott | 1 | $22 |
| Biotronik Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,038 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $64,799 |
| JardianceEmpagliflozin | 52 | $47,108 |
| MounjaroTirzepatide | 13 | $13,529 |
| LinzessLinaclotide | 12 | $10,357 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,540 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,448 |
| Rosuvastatin Calcium | 111 | $1,933 |
| Atorvastatin Calcium | 170 | $1,654 |
| Clonidine | 11 | $1,235 |
| Levothyroxine Sodium | 85 | $1,110 |
| Metoprolol Succinate | 97 | $1,084 |
| Pantoprazole Sodium | 57 | $1,026 |
| Mirtazapine | 17 | $951 |
| Amlodipine Besylate | 146 | $881 |
| Losartan Potassium | 81 | $864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $945 | $64,79967 claims |
| Boehringer IngelheimJardiance | $80 | $47,10852 claims |
| Lilly USA, LLCMounjaro | $221 | $13,52913 claims |
| AbbVieLinzess, Synthroid | $667 | $10,51625 claims |
| GSKIncruse Ellipta | $354 | $3,44811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Tinton Falls
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.